Explore our Services
Dobson | DaVanzo routinely assists clients who wish to submit their studies to peer reviewed journals. Our analysts and data scientists help to develop the “story line,” and tailor the content and format to the requirements of the selected journal. We are currently preparing three manuscripts for clients based on our analysis of the 100 percent Medicare files.
As subcontractor to BAH, Dobson | DaVanzo will collaborate on technical aspects of the development and implementation of formative and impact evaluations as well as on innovative techniques to estimate a Return on Investment to CMS.
Dobson | DaVanzo has been helping manufacturers and service providers of focused ultrasound (FUS) devices in understanding how CMS sets Ambulatory Payment Classification (APC) payment amounts in the outpatient setting.
Using CMS Innovation Award Data, Dobson|DaVanzo is helping physicians and physician group practices “deep dive” into the complex world of MIPS VBP cost efficiency measures by dissecting risk-adjusted Medicare spending during episodes of care for 18 medical conditions/surgical procedures by clinical theme, type of service, and episode period (pre-, intra-, and post-trigger periods) compared to peer-group benchmarks. This allows providers to easily identify areas for improvement. Our monthly and quarterly data updates provide timely information that allows providers to continually monitor their performance trend overtime.
COVID-19 cases are currently on the decline in the U.S. and effective vaccines have been developed, approved and are being distributed at record pace – all cause for celebration. However, new variants and societal fatigue are continuing dangers to the health and well-being of Americans as the government and healthcare industry race to vaccinate and protect people from the novel pathogen. As we complete our first full year living in the COVID-19 public health emergency, this blog explores two questions worth asking:
- How far are we into this pandemic (in terms of herd immunity); and
- What are our policy options to take advantage of this recent decline in cases and steadily increasing availability of vaccines?